News

Boston Scientific Renal Denervation Vessix Vascular

November 8, 2012 — Boston Scientific Corp. is extending its reach into the renal denervation market by signing a...

November 7, 2012 — Kona Medical Inc. announced the initiation of the first clinical study of its device...

Xarelto rivaroxaban Janssen Pharmaceuticals Deep Vein Thromosis Treament

Janssen Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has approved rivaroxaban (Xarelto), an oral anticoagulant, for the...

Paradise System ReCor Medical Hypertension Therapies Renal Denervation

November 5, 2012 — ReCor Medical reported one-year follow-up data on patients who have been treated via renal denervation...

ADAPT-DES study TCT, 2012, Plavix, stent

November 2, 2012 — Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible...

October 23, 2012 — A study found that a tailored therapy approach that adjusts the loading dose of clopidogrel according to measured platelet reactivity is superior to prasugrel therapy in...

October 16, 2012 — Proteon Therapeutics Inc. has initiated enrollment in a Phase 1 clinical study of its lead product, PRT-201, in patients with symptomatic peripheral artery disease (PAD) of the...

Pharmaceuticals Eliquis Apixaban

This year’s European Society of Cardiology (ESC) Congress in Munich, Germany, was a stark example of exactly where the cardiovascular market space is headed. This congress fully emphasized the new...

October 3, 2012 — Sharp Memorial Hospital was the first on the West Coast to participate in Medtronic's SYMPLICITY HTN-3 clinical trial in March, and is currently the leading trial site in ...

October 2, 2012 — AstraZeneca has announced the results from a sub-analysis of PLATO that evaluated the effects of age on clinical outcomes in patients with acute coronary syndrome (ACS). Results...

October 2, 2012 — A novel blood thinner recently approved by the U.S. Food and Drug Administration (FDA), Pradaxa (dabigatran), has been rapidly adopted into clinical practice, yet thus far has...

Pfizer Bristol-Myers Squibb Eliquis

October 1, 2012 — Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the new drug application (NDA) resubmission...

September 28, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-...

September 25, 2012 — Patients are often aggressively treated with anticoagulants, or blood thinners, to help prevent...

The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at next month's ...

September 13, 2012 — Janssen Research & Development LLC announced that it has submitted the complete response to the U.S. Food and Drug Administration (FDA) for the use of Xarelto (rivaroxaban...

September 7, 2012 — St. Jude Medical Inc. announced results of the FAME II trial demonstrating that patients with...

September 6, 2012 — Daiichi Sankyo Co. Ltd. and Eli Lilly and Co. announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in...

August 30, 2012 — Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination...